solution for infusion

DRUG4 trials

Sponsors

Seelos Therapeutics Inc., Universite De Liege, CHU De Liege, Bristol-Myers Squibb Services Unlimited Company, Grifols Therapeutics LLC

Conditions

Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk FactorsChronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Disorder of ConsciousnessSpinocerebellar Ataxia type-3 (SCA3)severe brain injury

Phase 2

A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL TO ASSESS SAFETY AND EFFICACY OF SLS-005 (TREHALOSE INJECTION, 90.5 MG/ML FOR INTRAVENOUS INFUSION) FOR THE TREATMENT OF ADULTS WITH SPINOCEREBELLAR ATAXIA

CompletedCTIS2022-501004-10-00

Seelos Therapeutics Inc.Spinocerebellar Ataxia type-3 (SCA3)

Start: 2023-01-30End: 2024-02-12Target: 58Updated: 2023-03-10

Treating severe brain-injured patients with apomorphine : a behavioural and neuroimaging study

RecruitingCTIS2023-504631-40-01

Universite De Liege, CHU De LiegeDisorder of Consciousness, severe brain injury

Start: 2018-09-05Target: 102Updated: 2025-07-24

Phase 3

A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors

Active, not recruitingCTIS2023-508264-29-00

Bristol-Myers Squibb Services Unlimited CompanyAdvanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors

Start: 2019-06-11Target: 254Updated: 2025-12-05

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Not yet recruitingCTIS2025-522165-30-00

Grifols Therapeutics LLCChronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Target: 6Updated: 2026-07-07